Search PubMed⌕ Search

Biomedical subjects

T Takeuchi

Publications and source records attributed to T Takeuchi.

At least 919 records · Page 51Linked to original sources
PubMed1993

[Urinary incontinence following total prostatectomy--evaluation by urodynamics and urethrography].

Urinary incontinence following total prostatectomy was evaluated in 10 patients by urodynamics and lateral urethrography. The pathological stage of the tumors in these patients was pT2 in 5 patients, pT3 in 3 patients and pT4 in 2 patients. Urinary incontinence was present in 8 patients, of whom 7 were stress incontinence and one was urge and stress incontinence. The severity of incontinence of these patients was mild in 5 patients, moderate in 3 and severe in 2. The incontinence was severer in the patients with the tumors of pT3 or pT4 than in the patients with the tumors of pT2. But the severity of incontinence was not related to the pathological grade or resected weight of the tumors. The bladder capacity and bladder compliance were 214.9 ml and 14.3 ml/cmH2O in average, respectively, and was not related to severity of incontinence. The statistical significant differences between continence or mild incontinence patients and moderate or severe incontinence patients were found for the mean functional profile length (2.04 versus 1.37 cm, respectively; p < 0.05) and maximum urethral closure pressure (42.3 versus 17.3 cmH2O, respectively; p < 0.05). But some patients with continence or mild incontinence demonstrated low values in either parameters. No statistical difference was found between continence and mild incontinence patients. On lateral urethrography, the posterior urethrovesical angle was not correlated with the severity of incontinence.

Aged↗
PubMed1993

[Transurethral endoureteropyelotomy].

Transurethral endoureteropyelotomy was performed in a total of 37 patients with primary ureteropelvic junction obstruction or various ureteral strictures. Thirty-one (84%) of the 37 evaluable patients showed a radiographical improvement of hydronephrosis with a mean follow-up period of 15.8 +/- 10.5 months (range: 3-40). The clinical success rates were as follows: primary ureteropelvic junction obstruction, 11/12 92%); upper ureteral stricture, 6/7 (86%); lower ureteral stricture, 14/18 (78%). This endourological procedure required a mean operation time of 38.0 +/- 27.7 minutes and hospital stay of 7.3 +/- 4.9 days. No major complication has been identified. This retrograde procedure has a straight access to the strictured segment of ureteropelvic junction. It is safe and less invasive to the renal parenchym as it does not require percutaneous nephrostomy. Therefore, it might be clinically useful for the treatment of primary ureteropelvic junction obstruction and other ureteral strictures.

Adolescent↗
PubMed1993

Delaminomycins, novel extracellular matrix receptor antagonist. IV. Structure-activity relationships of delaminomycins and derivatives.

Delaminomycins A, B, C and their derivatives were prepared and investigated biological activities of them. Among these compounds, spiro compounds (A2, B2 and C2) showed stronger inhibitory activity than natural products (A1, B1 and C1) on B16 melanoma cells adhesion assay and Con A-induced proliferation of murine splenic lymphocytes assay. In MLCR and antimicrobial assay, however, A1, B1 and C1 showed more potent inhibitory activity than spiro compounds (A2, B2 and C2). On the other hand, as to C-5' substituents of pyrrolidine ring, the order of inhibitory activity was R = OH > R = OCH3 > R = H on Con A-induced proliferation of murine splenic lymphocytes assay. In MLCR and antimicrobial assay, however, the order of inhibitory activities were R = H > R = OCH3 > R = OH. Inhibitory activities of A4 which was lacked pyrrolidine ring were reduced on B16 melanoma cells adhesion assay and on cytotoxicity against tumor cells in vitro in comparison with those of A1.

Animals↗
PubMed1993

Microbial glycosidation of some anthracycline antibiotics by an antibiotic-negative mutant of aclarubicin producer.

Microbial conversion of anthracyclinone monosaccharides using aclarubicin-negative mutant of Streptomyces galilaeus was found to produce anthracyclinone disaccharides which had either rhodinose or 2-deoxyfucose as an additional sugar. By this conversion we obtained twelve new anthracyclines from seven anthracyclines which had rhodosamine, N-monomethyldaunosamine or daunosamine at C-7 as a glycosidic sugar. All products had a reduced cytotoxic activity in comparison with those of parent compounds. However, some of them showed a therapeutically improved antitumor effects against L1210 leukemia in vivo.

Aclarubicin↗
PubMed1993

Dephostatin, a novel protein tyrosine phosphatase inhibitor produced by Streptomyces. I. Taxonomy, isolation, and characterization.

A novel inhibitor of protein tyrosine phosphatase, dephostatin, was isolated from the culture broth of a strain of Streptomyces. The active principle was extracted from the broth filtrate with ethyl acetate and purified by silica gel chromatography and by HPLC. Dephostatin inhibited protein tyrosine phosphatase prepared from a human neoplastic T-cell line with an IC50 at 7.7 microM. The inhibitory pattern of dephostatin was competitive against the substrate. Dephostatin inhibited the growth of Jurkat cells.

Cell Division↗
PubMed1993

IC101, extracellular matrix antagonist produced by Streptomyces sp. MJ202-72F3. Production, isolation, structure determination and biological activity.

In our search for inhibitors of cell adhesion to components of extracellular matrix (ECM), fibronectin, laminin and collagen type IV, we succeeded in finding a novel cyclic hexadepsipeptide antibiotic, named IC101, which was isolated from cultured mycelium of Streptomyces albulus MJ202-72F3. It was purified by centrifugal partition chromatography, preparative reverse phase HPLC and Sephadex LH-20 and was obtained as a white powder. IC101 strongly inhibited cell adhesion to ECM components, suppressed immune responses in vitro and in vivo, and exhibited antimicrobial activity on Gram-positive bacteria.

Animals↗
PubMed1993

T cell activation by conagenin in mice.

Conagenin (CNG), a low molecular immunomodulator, enhanced incorporation of [3H]thymidine into T cells activated by concanavalin A but did not to non-activated T cells. The culture supernatants of activated T cells treated with CNG enhanced incorporation of [3H]thymidine into cytokine dependent cell lines, CTLL-2 and IC-2 cells. This indicates that CNG exclusively acts on activated T cells and stimulates them to promote DNA synthesis and to produce lymphokines, which may include T cell growth factors and hematopoietic growth factors. These activities were also observed with T cells taken from mice given CNG.

Adjuvants, Immunologic↗
PubMed1993

Effect of conagenin in tumor bearing mice. Antitumor activity, generation of effector cells and cytokine production.

Antitumor effects and function of T cells in tumor bearing mice given conagenin (CNG), a low molecular immunomodulator, were investigated. The administration of CNG, once a week for 4 weeks, was the most effective schedule in inhibiting growth of IMC carcinoma, a syngeneic tumor. In this regimen, cytotoxic T lymphocytes and natural killer activities in spleens of CNG treated mice were maintained at higher levels than those of non-treated mice. Lymphokine production by splenic T cells was also enhanced in cultures, whereas monokine production by macrophages, which was increased in accordance with tumor growth, was reduced by CNG administration. The antitumor effect of CNG was not observed in mice given anti-asialo GM1 serum and in athymic mice. Results shown in this report suggest that CNG exerts its antitumor effects through activation of T cells and enhancement of generation of antitumor effector cells.

Adjuvants, Immunologic↗
PubMed1993

AB5046A and B, novel chlorosis-inducing substances from Nodulisporium sp.

Novel chlorosis-inducing substances, AB5046A and B, were isolated from the culture broth of a fungal strain. The producing organism, designated AB5046, was identified as a member of Nodulisporium. AB5046A and B were purified by extraction with EtOAc and silica gel chromatography. The structure of AB5046A and B were determined to be 2-butyryl-3,5-dihydroxy-cyclohex-2-ene-1-one and 2-acetyl-3,5-dihydroxy-cyclohex-2-ene-1-one, respectively, by spectroscopic analyses. AB5046A and B induced chlorosis against Japanese barnyard millet in vitro. The chlorosis activity of these compounds was stronger against monocotyledons than dicotyledons.

Animals↗